Related SPY U.S. Dollar Books 7th Consecutive May Gain S&P 500 Index Futures Trading Lower NexPoint Credit Strategies Fund: The High-Conviction Activist Fund (Seeking Alpha)
Related TLT 3 Trades To Make After Draghi's Comments How Bond ETF Flows Affect ETF Sponsors 5 Reasons To Be Bullish On Stocks (Seeking Alpha)
Historically, bond yields and equity prices are inverse. If bond yields rise, then equities decline and vice versa. With Wall Street continuously over-analyzing the FOMC rate hike probability in effort to prove their worth (news flash, the probability is always 50 percent, they either raise or they don't,), Citigroup has decided to make a splash by saying rising yields and weak equity price returns appears more complicated when reviewing history than what we were taught inside those Ivory towers by academics.
best shares to invest in now: Brown(n)
- [By Arie Goren]
On November 5, Oracle (NYSE:ORCL)confirmed that it has finally completed the acquisition of Netsuite (NYSE:N) for $9.3 billion in cash, or $109 per share that the company had initially offered. In my previous article about Oracle, I had suggested that the acquisition of NetSuite, the cloud business application software company, is a smart move by Oracle. What’s more, it is not paying an excessive price for the deal. In fact, Oracle insisted that it will not pay more than what it had first offered despite the resistance from T Rowe Price (NSDQ:TROW)which demanded $133 per share.
best shares to invest in now: RetailMeNot, Inc.(SALE)
- [By Demitrios Kalogeropoulos]
As for individual stocks, RetailMeNot (NASDAQ:SALE) and SUPERVALU (NYSE:SVU) attracted heavy investor interest following merger and acquisition news.
- [By Lisa Levin]
Shares of RetailMeNot Inc (NASDAQ: SALE) got a boost, shooting up 12 percent to $8.42. RetailMeNot announced after Thursday’s close it has entered into an agreement to acquire GiftCard Zen, a secondary marketplace for gift cards. The company reported preliminary Q1 revenue of $54 million to $54.5 million and FY16 revenue of $228 million to $241 million.
best shares to invest in now: Neovasc Inc.(NVCN)
- [By Lisa Levin]
Neovasc Inc (US) (NASDAQ: NVCN) shares were also up, gaining 71 percent to $0.880 following announcement of an agreement with Boston Scientific Corporation (NYSE: BSX).
- [By Lisa Levin] Related NVCN 18 Biggest Mid-Day Losers For Wednesday Legal Overhangs Keep Ladenburg Neutral On Neovasc Despite Positive Tiara Clinical Data Boston Scientific closes Neovasc transaction (Seeking Alpha)
Related BSX Watch These 10 Huge Call Purchases In Monday Trade Wonderful Wearables Get Their Own ETF Boston Scientific closes Neovasc transaction (Seeking Alpha) Gainers
Neovasc Inc (US) (NASDAQ: NVCN) rose 17.3 percent to $2.65 in pre-market trading after the company reported the close of its $75 million transaction with Boston Scientific Corporation (NYSE: BSX).
aTyr Pharma Inc (NASDAQ: LIFE) shares rose 12.3 percent to $4.10 in pre-market trading after the company disclosed 'promising' signals in myopathies with Resolaris in exploratory trials.
Globus Maritime Ltd (NASDAQ: GLBS) shares rose 10.1 percent to $6.90 in pre-market trading after climbing 5.03 percent on Monday.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares rose 9.9 percent to $3.00 in pre-market trading. Aurinia Pharmaceuticals appointed Lorin Jeffry “Jeff” Randall to its board and Chairman of the Audit Committee.
Ocean Rig UDW Inc. (NASDAQ: ORIG) shares rose 8.7 percent to $2.89 in pre-market trading after surging 19.82 percent on Monday.
Full House Resorts, Inc. (NASDAQ: FLL) shares rose 5.1 percent to $2.08 in pre-market trading after declining 1.98 percent on Monday.
Seadrill Ltd (NYSE: SDRL) rose 5.1 percent to $4.13 in pre-market trading after surging 3.15 percent on Monday.
Noble Corporation (NYSE: NE) rose 5.1 percent to $7.60 in pre-market trading after declining 5.37 percent on Monday.
Arbutus Biopharma Corp (NASDAQ: ABUS) rose 5.1 percent to $3.10 in pre-market trading. Arbutus issued additional data from its ARB-1467 Phase II
- [By Paul Ausick]
Neovasc Inc. (NASDAQ: NVCN) fell about 21% Wednesday to post a new 52-week low of $0.26 after closing at $0.33 on Tuesday. The 52-week high is $2.12. Volume of about 7.3 million was around 7 times the daily average. The medical device maker had no specific news.
best shares to invest in now: Ultra Clean Holdings, Inc.(UCTT)
- [By Lisa Levin]
In trading on Monday, technology shares fell 0.65 percent. Meanwhile, top losers in the sector included Ultra Clean Holdings Inc (NASDAQ: UCTT), down 4 percent, and Mitek Systems, Inc. (NASDAQ: MITK), down 7 percent.
- [By Lisa Levin]
In trading on Friday, technology shares fell 3.59 percent. Meanwhile, top losers in the sector included Ultra Clean Holdings Inc (NASDAQ: UCTT), down 5 percent, and Brooks Automation, Inc (NASDAQ: BRKS), down 10 percent.
best shares to invest in now: Daiichi Sankyo Company, Limited (DSKYF)
- [By SEEKINGALPHA.COM]
According to Bob Radie (see transcript of January 9th teleconference), the company’s president and chief executive officer, a key consideration in the denial was the FDA’s granting, in November 2016, rival product MorphaBond three-year exclusivity for the intranasal route of abuse. Significantly, though, even though MorphaBond – developed by tiny, privately-owned Inspirion Delivery Technologies – was approved in October 2015, it is yet to be commercialized. An October 25, 2016, marketing agreement between Inspirion and Japan-based Daiichi Sankyo, Inc. (OTCPK:DSKYF) suggests MorphaBond could be launched in the near future, but it’s also important to note that the aforementioned exclusivity expires on October 2, 2018, at which point Egalet will be able to include the clinical data from its intranasal abuse potential study in its label.
best shares to invest in now: Monro Muffler Brake, Inc.(MNRO)
- [By Ben Levisohn]
Yesterday, shares of Monro Muffler Brake (MNRO) plunged 3.1% after Barron’s Leslie Norton panned the stock in this weekend’s issue of the magazine. And wouldn’t you know it? Monro’s shares are skidding lower once again today.
Norton’s argument was straightforward:
At a recent $62, Rochester, N.Y.based Monro (ticker: MNRO) trades at a lofty 28 times forward earnings, compared with a 10-year average of 21.1, and 17 times earnings for the Standard & Poors 500. With sales growth slowing as competition increases, Monros strategic goal of achieving 15% annual sales gains and 20% profit growth seems distant.
Any hint of more sluggish sales could push the shares down at least 10%. Bruce Geller, CEO of money manager Dalton Greiner Hartman Maher, who is short the stock, says, A fairly commoditized business with low organic growth deserves a more reasonable multiple of 20 times.
That would put the stock in the mid-$40s.
Shares of Monro Muffler Brake have dropped 4% to $57.59 at 3:49 p.m. today, leaving around 20% of downside.
UPDATE: This post initially misspelled ‘Brake’ as ‘Break.’ It’s been corrected.